Foghorn Therapeutics Inc.

Informe acción NasdaqGM:FHTX

Capitalización de mercado: US$255.1m

Foghorn Therapeutics Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Adrian H. Gottschalk

Chief Executive Officer (CEO)

US$2.5m

Compensación total

Porcentaje del salario del CEO23.1%
Permanencia del CEO7yrs
Participación del CEO1.2%
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adrian H. Gottschalk en comparación con los beneficios de Foghorn Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023US$3mUS$579k

-US$98m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$115m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$5mUS$575k

-US$109m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$109m

Mar 31 2022n/an/a

-US$105m

Dec 31 2021US$4mUS$540k

-US$101m

Sep 30 2021n/an/a

-US$93m

Jun 30 2021n/an/a

-US$85m

Mar 31 2021n/an/a

-US$78m

Dec 31 2020US$3mUS$479k

-US$69m

Sep 30 2020n/an/a

-US$63m

Jun 30 2020n/an/a

-US$58m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$1mUS$465k

-US$51m

Compensación vs. Mercado: La compensación total de Adrian H.($USD2.50M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.63M).

Compensación vs. Ingresos: La compensación de Adrian H. ha sido consistente con los resultados de la empresa en el último año.


CEO

Adrian H. Gottschalk (47 yo)

7yrs

Permanencia

US$2,503,942

Compensación

Mr. Adrian H. B. Gottschalk serves as President, Chief Executive Officer and a Director of Foghorn Therapeutics Inc. since May, 2017. Prior to joining Foghorn and since 2004, Mr. Gottschalk worked at Bioge...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Adrian H. Gottschalk
President7yrsUS$2.50m1.2%
$ 3.1m
Steven Bellon
Chief Scientific Officer2.3yrsUS$1.19m0.40%
$ 1.0m
Alfonso Cardama
Chief Medical Officerless than a yearUS$1.84msin datos
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno datasin datossin datos
Kristian Humer
Chief Financial Officerless than a yearsin datossin datos
Karin Hellsvik
VP, Corporate Affairs & Investor Relationsless than a yearsin datossin datos
Michael LaCascia
Chief Legal Officer3.5yrsUS$1.99m0%
$ 0
Saurabh Sewak
Vice President of Corporate Development2.3yrssin datossin datos
Carlos Costa
Chief People Officerno datasin datossin datos
Fanny Cavalie
Chief Strategy & Business Operations Officerno datasin datos0.18%
$ 455.4k

2.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de FHTX se considera experimentado (2.3 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Adrian H. Gottschalk
President7yrsUS$2.50m1.2%
$ 3.1m
Gerald Crabtree
Founder & Member of Scientific Advisory Boardno datasin datossin datos
B. Parshall
Independent Director1.8yrsUS$157.65k0%
$ 0
Balkrishan Gill
Independent Director6.8yrsUS$159.07k0.080%
$ 204.1k
Douglas Cole
Founder & Independent Chairman of the Board8.6yrsUS$184.57k0%
$ 0
Charles Sawyers
Member of Scientific Advisory Boardno datasin datossin datos
David Schenkein
Member of Scientific Advisory Boardno datasin datossin datos
Anthony Kouzarides
Member of Scientific Advisory Boardno datasin datossin datos
Adam Koppel
Independent Director6.8yrsUS$153.07k0%
$ 0
Michael Mendelsohn
Independent Director7.1yrsUS$154.57k0%
$ 0
Scott Biller
Independent Director4.3yrsUS$145.57k0%
$ 0
Cigall Kadoch
Member of Scientific Advisory Board1.7yrsUS$252.52k8.51%
$ 21.7m

6.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de FHTX se considera experimentada (6.8 años de antigüedad promedio).